Eli Lilly and Stock Forecast for 2023 - 2025 - 2030

Updated on 03/28/2024

Stock Rating
16
Price Target
$813.00
Consensus
Outperform
Upside
10.71%
Analysts
9
Stock Rating
16
Upside
10.71%
Analysts
9
Price Target
$813.00

Eli Lilly and Stock Forecast and Price Target

Based on the current earnings figures, this year's price targets for Eli Lilly and were recently set by nine distinguished experts, with an average mark of $813.00. If it reached this goal, it would represent a potential upside of approximately 10.71% from the previous closing price in March, 2024. The high end is $1000.00, and the low is $500.00. If you're looking for information on Eli Lilly and stock, consider checking out the forecasts for comparable firms such as NYSE:BMY.

$813.00

10.71% Upside

Outperform
Outperform

Eli Lilly and Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Eli Lilly and's Price has gone down from $250.75 to $0.00 – a 100.00% drop. In the next year, analysts believe that Fair Value will reach $371.22 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.

2024 Fair Value Forecast
$371.22
2025 Fair Value Forecast
$449.64
2026 Fair Value Forecast
$508.77
2027 Fair Value Forecast
$538.17
2028 Fair Value Forecast
$587.82
2029 Fair Value Forecast
$613.11
2030 Fair Value Forecast
$639.99
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
NOVO B Stock Forecast Novo Nordisk A/S Outperform 12
kr895.10 Buy/Sell kr696.07 6.13%
MRK Stock Forecast Merck Outperform 2
$122.77 Buy/Sell $130.51 9.96%
TMO Stock Forecast Thermo Fisher Scientific Outperform 10
$599.43 Buy/Sell $591.94 0.10%
ROG Stock Forecast Roche Holding Hold 16
CHF242.00 Buy/Sell CHF307.83 11.57%
ABT Stock Forecast Abbott Laboratories Outperform 9
$120.19 Buy/Sell $118.92 4.83%

Eli Lilly and Revenue Forecast for 2023 - 2025 - 2030

Eli Lilly and's Revenue has seen growth In the last three years, going from $24.54B to $34.12B – a gain of 39.06% In the next year, analysts believe that Revenue will reach $34.27B – an increase of 0.42%. For the next seven years, the forecast is forRevenue to grow by 40.51%.

2024 Rev Forecast
$34.27B
2025 Rev Forecast
$38.90B
2026 Rev Forecast
$42.26B
2027 Rev Forecast
$43.57B
2028 Rev Forecast
$45.83B
2029 Rev Forecast
$47.19B
2030 Rev Forecast
$47.95B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AZN Stock Forecast AstraZeneca PLC Outperform 17
£104.50 Buy/Sell £165.99 53.79%
NOVN Stock Forecast Novartis Outperform 10
CHF88.80 Buy/Sell CHF105.00 23.95%
PFE Stock Forecast Pfizer Outperform 2
$28.37 Buy/Sell $32.87 10.82%

Eli Lilly and Dividend per Share Forecast for 2023 - 2025 - 2030

In the last three years, Dividend per Share for Eli Lilly and has grown by 52.70%, going from $2.96 to $4.52. In the coming year, analysts are expecting an increase in Dividend per Share, predicting it will reach $4.68 – an increase of 3.54%. Over the next seven years, experts anticipate that Dividend per Share growth for Eli Lilly and will be 165.27%.

2024 DPS Forecast
$4.68
2025 DPS Forecast
$5.34
2026 DPS Forecast
$5.47
2027 DPS Forecast
$7.88
2028 DPS Forecast
$9.07
2029 DPS Forecast
$10.43
2030 DPS Forecast
$11.99
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMGN Stock Forecast Amgen Outperform 4
$275.36 Buy/Sell $303.65 14.40%
SAN Stock Forecast Sanofi Outperform 16
88.32€ Buy/Sell 102.80€ 21.15%
BMY Stock Forecast Bristol-Myers Squibb Hold 2
$54.36 Buy/Sell $58.15 1.18%

Eli Lilly and Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
$9.32B
2025 FCF Forecast
$10.94B
2026 FCF Forecast
$12.77B
2027 FCF Forecast
$14.28B
2028 FCF Forecast
$14.82B
2029 FCF Forecast
$15.14B
2030 FCF Forecast
$15.12B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$75.32 Buy/Sell $87.82 10.20%
GSK Stock Forecast GSK Outperform 12
£16.75 Buy/Sell £17.30 11.04%
ZTS Stock Forecast Zoetis Outperform 18
$183.49 Buy/Sell $220.47 20.72%

Eli Lilly and EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Eli Lilly and's EBITDA has increased by 46.16%, going from $8.43B to $12.31B. In the next year, analysts are expecting an increase in EBITDA, predicting it will reach $14.01B – an increase of 13.76%. The Eli Lilly and forecast is for EBITDA to reach $20.45B or grow by 66.07%.

2024 EBITDA Forecast
$14.01B
2025 EBITDA Forecast
$17.51B
2026 EBITDA Forecast
$16.01B
2027 EBITDA Forecast
$17.17B
2028 EBITDA Forecast
$17.93B
2029 EBITDA Forecast
$18.95B
2030 EBITDA Forecast
$20.45B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
4519 Stock Forecast Chugai Pharmaceutical Outperform 6
¥6.51k Buy/Sell ¥4.92k -5.57%
SUNPHARMA Stock Forecast Sun Pharmaceutical Industries Outperform 8
Rp1.59k Buy/Sell Rp1.52k -1.42%
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 5
¥4.31k Buy/Sell ¥4.74k 6.63%

Eli Lilly and EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Eli Lilly and's EBIT has grown, increasing from $7.10B to $10.79B – an increase of 51.90%. For next year, the 17 analysts predict EBIT of $12.44B, which would mean an increase of 15.36%. Over the next seven years, the pros' prediction is EBITof $19.90B, which would mean a seven-year growth forecast of 84.45%.

2024 EBIT Forecast
$12.44B
2025 EBIT Forecast
$15.21B
2026 EBIT Forecast
$16.48B
2027 EBIT Forecast
$18.00B
2028 EBIT Forecast
$19.05B
2029 EBIT Forecast
$19.75B
2030 EBIT Forecast
$19.90B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MRNA Stock Forecast Moderna Outperform 16
$111.98 Buy/Sell $135.42 11.09%
BAYN Stock Forecast Bayer Hold 5
26.82€ Buy/Sell 45.15€ 26.77%
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$149.10 Buy/Sell $245.24 44.20%

Eli Lilly and EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Eli Lilly and's EPS has gone down from $7.93 to $0.00 – a 100.00% drop. In the next year, analysts believe that EPS will reach $11.74 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.

2024 EPS Forecast
$11.74
2025 EPS Forecast
$14.22
2026 EPS Forecast
$16.09
2027 EPS Forecast
$17.02
2028 EPS Forecast
$18.59
2029 EPS Forecast
$19.39
2030 EPS Forecast
$20.24
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BGNE Stock Forecast BeiGene Buy 6
$164.53 Buy/Sell $285.19 67.14%
TEVA Stock Forecast Teva Pharmaceutical Industries Outperform 12
$13.35 Buy/Sell $11.59 19.85%
4507 Stock Forecast Shionogi & Outperform 18
¥7.87k Buy/Sell ¥7.12k 1.70%